- Home
- IBRX vs CWST Comparison
IBRX vs CWST Comparison
Compare IBRX & CWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IBRX | CWST |
|---|---|---|
| Founded | 2014 | 1975 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Environmental Services |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 5.9B |
| IPO Year | 2015 | 1997 |
Fundamental Metrics
Financial Performance| Metric | IBRX | CWST |
|---|---|---|
| Price | $7.94 | $91.40 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | $12.57 | ★ $117.50 |
| AVG Volume (30 Days) | ★ 31.4M | 895.0K |
| Earning Date | 05-18-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.71 | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | $113,288,000.00 | ★ $1,836,841,000.00 |
| Revenue This Year | $88.57 | $10.03 |
| Revenue Next Year | $146.98 | $6.48 |
| P/E Ratio | ★ N/A | $756.67 |
| Revenue Growth | ★ 668.31 | 17.95 |
| 52 Week Low | $1.83 | $82.22 |
| 52 Week High | $12.43 | $121.20 |
Technical Indicators
Market Signals| Indicator | IBRX | CWST |
|---|---|---|
| Relative Strength Index (RSI) | 49.64 | 41.45 |
| Support Level | $2.27 | $85.31 |
| Resistance Level | $8.28 | $91.13 |
| Average True Range (ATR) | 1.03 | 3.73 |
| MACD | -0.33 | -0.31 |
| Stochastic Oscillator | 3.33 | 36.68 |
Price Performance
Historical ComparisonAbout IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About CWST Casella Waste Systems Inc.
Casella Waste Systems Inc is a solid waste removal company, providing resource management services to residential, commercial, municipal, and industrial customers. The company's reportable segments on Geographical basis include Eastern, Western and Mid-Atlantic regions through the Resource solution segment. It generates maximum revenue from the Western region segment. The company's services include Recycling, Collection, Organics, Energy, Landfills, Special Waste as well as Professional Services.